Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:41 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients
NCT03064854 · Novartis Pharmaceuticals · PHASE1 · terminated · last registry update 2022-08-15 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Recruitment halted prematurely due to competitive landscape for lung cancer therapies” | Open Targets' class: study design | Registry record, Novartis Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PDCD1 in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-06-27Phase 3 first posted: Amgen, Sotorasib + Pembrolizumab (NCT05920356)
- 2022-09-27Phase 3 first posted: Daiichi Sankyo, Datopotamab Deruxtecan + Pembrolizumab (NCT05555732)
- 2022-06-23Phase 3 first posted: Second Affiliated Hospital, Zhejiang University, School of Medicine, Sintilimab + Carboplatin (NCT05429463)
- 2021-09-17Phase 3 first posted: AstraZeneca, Trastuzumab Deruxtecan + Cisplatin (NCT05048797)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision